1. Home
  2. MAIA vs MYND Comparison

MAIA vs MYND Comparison

Compare MAIA & MYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • MYND
  • Stock Information
  • Founded
  • MAIA 2018
  • MYND 1998
  • Country
  • MAIA United States
  • MYND United States
  • Employees
  • MAIA N/A
  • MYND N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • MYND Other Consumer Services
  • Sector
  • MAIA Health Care
  • MYND Real Estate
  • Exchange
  • MAIA Nasdaq
  • MYND Nasdaq
  • Market Cap
  • MAIA 46.7M
  • MYND 38.8M
  • IPO Year
  • MAIA 2022
  • MYND 2017
  • Fundamental
  • Price
  • MAIA $2.03
  • MYND $0.85
  • Analyst Decision
  • MAIA
  • MYND
  • Analyst Count
  • MAIA 0
  • MYND 0
  • Target Price
  • MAIA N/A
  • MYND N/A
  • AVG Volume (30 Days)
  • MAIA 319.8K
  • MYND 43.7K
  • Earning Date
  • MAIA 05-20-2025
  • MYND 05-20-2025
  • Dividend Yield
  • MAIA N/A
  • MYND N/A
  • EPS Growth
  • MAIA N/A
  • MYND N/A
  • EPS
  • MAIA N/A
  • MYND N/A
  • Revenue
  • MAIA N/A
  • MYND $267,380,999.00
  • Revenue This Year
  • MAIA N/A
  • MYND N/A
  • Revenue Next Year
  • MAIA N/A
  • MYND N/A
  • P/E Ratio
  • MAIA N/A
  • MYND N/A
  • Revenue Growth
  • MAIA N/A
  • MYND N/A
  • 52 Week Low
  • MAIA $1.40
  • MYND $0.61
  • 52 Week High
  • MAIA $5.99
  • MYND $3.89
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 53.91
  • MYND 57.62
  • Support Level
  • MAIA $1.80
  • MYND $0.70
  • Resistance Level
  • MAIA $2.18
  • MYND $0.98
  • Average True Range (ATR)
  • MAIA 0.30
  • MYND 0.07
  • MACD
  • MAIA -0.01
  • MYND 0.03
  • Stochastic Oscillator
  • MAIA 30.29
  • MYND 73.50

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About MYND Mynd.ai Inc.

Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more.

Share on Social Networks: